Early Morning Trend | SINO BIOPHARM is consolidating with reduced volume, is a policy change in the sector triggering a window?

SINO BIOPHARM (1177.HK) showed relatively calm performance during the trading session on the 16th, with the stock price weakly consolidating and trading volume continuously shrinking, indicating a clear lack of market liquidity. Throughout the day, it repeatedly tested the HKD 6.7 level but lacked strong buying support. Institutions in the sector remained cautious, with the market waiting for new policy or industry change signals. The pharmaceutical sector overall performed weakly, with limited fluctuations in the market and no significant accumulation of positions by major players. The market focus was on the implementation of medical insurance negotiations, with ongoing industry pressure from the expansion of volume-based procurement, limiting profit expectations for several pharmaceutical companies. Anti-corruption efforts in the medical sector also dampened industry sentiment, leading major funds to choose to reduce risk exposure, limiting the rebound momentum of leading stocks. Some funds took profits at highs, repeatedly digesting trapped positions, and the pharmaceutical sector currently lacks structural driving forces. In terms of technical signals, MACD remains bearish, with the 5-day and 10-day moving averages pressing down, and the stock price repeatedly testing the key support at HKD 6.69. If it can hold this support in the short term, there is a possibility of stabilization, but the lack of accompanying volume requires event-driven stimuli to facilitate a reversal. The current market is mainly observing whether there will be national-level policy support for innovative drugs and quality assets. If the short-term support is breached, there is a possibility of inertia downward movement. The chance of a rebound from oversold conditions in the short term is increased by marginal positive news, but the overall sentiment in the sector requires clearer signals to warm up. Investors should pay attention to changes in policy direction and unusual volume movements, avoiding blind speculation